Completed PHASE4 INTERVENTIONAL NCT00160589

LEADER (LEvocetirizine And DEsloratadine in Allergic Rhinitis)

A Multicentre, Double-blind, Parallel, Randomized, Placebo-controlled Study : Evaluation of the Efficacy and Safety of Levocetirizine 5 mg and Desloratadine 5 mg Administered Orally as Capsules Once Daily, in the Morning, Over 2 Weeks in Patients Suffering From Allergic Rhinitis (AR)

Sponsor: UCB Pharma

Conditions Rhinitis, Allergic, Perennial

Interventions Levocetirizine

Updated 6 times since 2017 Last updated: Dec 13, 2013 Started: Apr 30, 2005 Primary completion: Sep 30, 2005 Completion: Sep 30, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00160589, this PHASE4 trial focuses on Rhinitis, Allergic, Perennial and remains completed. Sponsored by UCB Pharma, it has been updated 6 times since 2005, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Feb 2017 — Jun 2018 [monthly]

Completed PHASE4

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE4

First recorded

Apr 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

UCB Pharma

Data source: UCB Pharma

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.